Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
cipla
30 tablet
Gefitinib
Keep in cold place
Delivering To:
Overview
Gefticip 250mg tablet is a chemotherapy medication that is used in the treatment of non-small cell lung cancer (NSCLC). The generic name of this medication is Gefitinib. It is a tyrosine kinase inhibitor that shows antineoplastic activity. Gefticip is used in the first-line treatment of lung cancer that has genetic mutations.
Lung Cancer
Every medicine has some side effects that manage on their own as your body gets used to the medicine, but some people may rarely experience severe side effects. In that case, the patient should contact the doctor immediately.
Some common side effects of Entekor 1mg Tablet include:
Mouth sores
Dry skin
Loss of appetite
Blisters of skin
Vomiting
Hives on the skin
Shortness of breath
Dark coloration of urine
Yellowing of skin and eyes
Nausea
Sensitivity to light
Vision complications
Acne
Extreme weakness
Diarrhea
Seek medical attention in case of any unusual or severe side effects immediately.
The dosage and treatment duration of the Gefticip 250mg tablet are decided by the doctor according to the stage of cancer and the overall patient's health. This tablet should be taken with or without food, but at the fix time every day to get effective results. Don't miss a dose or overdose on the medicine.
Alcohol
unsafe
Avoid the consumption of alcohol while taking Gefticip 250mg tablet, as alcohol can reduce the effectiveness of the medicine and worsen the symptoms
Pregnancy
consult your doctor
Do not take the Gefticip 250mg tablet without consulting the doctor in case of pregnancy, as it is an unsafe medicine during this period.
Breast Feeding
consult your doctor
Gefticip 250mg tablet is dangerous to use during breastfeeding as it may cause toxicity to the baby.
Driving
danger
Gefticip 250mg tablet may cause side effects such as dizziness or impaired concentration, which could affect your ability to drive safely. So it's better to avoid driving or operating heavy machinery.
Kidney
caution
Consumption of Gefticip 250mg tablet should be avoided without informing the doctor if you have any kidney-related issues.
Liver
caution
Gefticip 250mg tablet is safe for use in liver disease. No dosage adjustment is necessary for this Tablet.
It is advisable to avoid missing any doses of Gefticip and in case you miss a dose of Gefticip consult your doctor immediately.
Gefticip 250mg tablet is an anticancer medication that is primarily used in the treatment of lung cancer.
Gefticip tablets are taken orally once a day or as advised by the doctor
The doctor decides how long the treatment with Gefticip will continue, depending on the condition, stage of cancer, and health of the patient.
It is advisable to avoid driving and operating heavy machinery as Gefticip causes dizziness as one of its side effects.
Gefticip 250mg can cause harm to the fetus; hence, it is advisable to avoid pregnancy or consult the doctor for the same.
At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.
Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.
Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.
We currently ship to:
Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!
1. Uhm, J. H., Ballman, K. V., Wu, W., Giannini, C., Krauss, J. C., Buckner, J. C., ... & Jaeckle, K. A. (2011). Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. International Journal of Radiation Oncology* Biology* Physics, 80(2), 347-353.
2. Herbst, R. S., Fukuoka, M., & Baselga, J. (2004). Gefitinib—a novel targeted approach to treating cancer. Nature Reviews Cancer, 4(12), 956-965.
3. Rawluk, J., & Waller, C. F. (2018). Gefitinib. Small molecules in oncology, 235-246.
4. Giaccone, G. (2004). The role of gefitinib in lung cancer treatment. Clinical cancer research, 10(12), 4233s-4237s.
5. Höpfner, M., Sutter, A. P., Huether, A., Schuppan, D., Zeitz, M., & Scherübl, H. (2004). Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. Journal of hepatology, 41(6), 1008-1016.
6. Araki, T., Yashima, H., Shimizu, K., Aomori, T., Hashita, T., Kaira, K., ... & Yamamoto, K. (2012). Review of the treatment of non-small cell lung cancer with gefitinib. Clinical Medicine Insights: Oncology, 6, CMO-S7340.
cipla
Written By
Venika Choudhary
Medical Content Writer @ Magicine Pharma
I hold an M.Sc. in Microbiology and have a strong academic foundation in microbial sciences and applied biotechnology. I began my career with extensive hands-on research at CSIR laboratories, focusing on fungal enzyme production, studying fungal diversity in various ecosystems, and developing bio-pesticides as sustainable alternatives to chemical pesticides. This work deepened my understanding of fungal biology, bioactive compounds, and their pharmaceutical and agricultural applications. Transitioning from research, I now work as a medical content writer, where I combine my scientific expertise with a passion for clear and reliable healthcare communication. I apply my research background to create patient-friendly, compliant content for pharmaceutical companies and healthcare platforms, ensuring science is both trustworthy and accessible. Specializing in clear, accurate, and engaging content, I help patients make informed decisions and support pharmaceutical companies in delivering trusted information. Whether writing product descriptions, crafting disease awareness articles, or composing drug information leaflets, I consistently meet regulatory standards and address audience needs, making my content an asset for healthcare brands.
Reviewed By
Dr. Aditya Sarin - MBBS, MD, DrNB - Consultant Medical Oncology
Dr. Aditya Sarin, MBBS, MD, DrNB, is a highly qualified medical oncologist with profound research and clinical expertise, currently working at Sir Ganga Ram Hospital, New Delhi. He is also a member of the European Society of Medical Oncology (ESMO), a non-profit European organization dedicated to eradicating cancer by promoting comprehensive cancer care and advancing medical oncology. He has been honored with several awards, including the International Cancer Foundation scholarship (ESMO congress, 2022) and Young Medical Oncologist of the Year (Times of India, 2024). He is well-known for his breakthrough in oncology. Dr. Sarin is passionate about converting complex health information into a concise and clear form that is understandable to everyone, aiming to create awareness and cancer care among people.